92 studies found for:    MPL
Show Display Options
Rank Status Study
1 Completed Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine
Condition: Type I Hypersensitivity
Intervention: Biological: Tree MATA MPL
2 Active, not recruiting LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine
Condition: Leishmaniasis
Interventions: Drug: SE;   Drug: MPL-SE;   Biological: LEISH-F3;   Drug: GLA-SE
3 Completed Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen
Condition: Type I Hypersensitivity
Intervention: Biological: Tree MATA MPL
4 Completed Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing
Condition: Type I Hypersensitivity
Intervention: Biological: Ragweed MATA MPL
5 Completed Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen
Condition: Type I Hypersensitivity
Intervention: Biological: OralvacB2MPL
6 Completed Efficacy and Safety/Tolerability of Grass MATA MPL
Condition: Type I Hypersensitivity
Interventions: Biological: Grass MATA MPL;   Biological: Placebo
7 Completed
Has Results
A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
Condition: Cutaneous Leishmaniasis
Interventions: Biological: LEISH-F2 + MPL-SE;   Drug: Sodium stibogluconate
8 Completed Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine Formulation A;   Biological: HBV-MPL vaccine Formulation B;   Biological: Engerix™-B
9 Completed Efficacy and Safety/Tolerability of Ragweed MATA MPL
Condition: Type I Hypersensitivity
Intervention: Biological: Ragweed MATA MPL
10 Completed Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine;   Biological: Engerix™-B
11 Completed Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine;   Biological: Engerix™-B
12 Completed Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules
Condition: Hepatitis B
Interventions: Biological: Engerix™-B;   Biological: HBV-MPL vaccine
13 Completed Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine
Condition: Type I Hypersensitivity
Intervention: Biological: Grass MATAMPL
14 Completed Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India
Conditions: Visceral Leishmaniasis;   Post-Kala-Azar Dermal Leishmaniasis
Intervention: Biological: Leish-111f + MPL-SE Adjuvant
15 Not yet recruiting Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine in Children
Condition: Norovirus
Interventions: Biological: GI.1/GII.4 (15/15) - MPL (50);   Biological: GI.1/GII.4 (15/50) - MPL (50);   Biological: GI.1/GII.4 (50/50) - MPL (50);   Biological: GI.1/GII.4 (15/15) - MPL (15);   Biological: GI.1/GII.4 (15/50) - MPL (15);   Biological: GI.1/GII.4 (50/50) - MPL (15);   Biological: GI.1/GII.4 (15/15);   Biological: GI.1/GII.4 (15/50);   Biological: GI.1/GII.4 (50/50);   Biological: GI.1/GII.4 (50/150);   Biological: GI.1/GII.4 (15/50) - Al(OH)3 (167);   Drug: Placebo
16 Completed Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL
Condition: Post Kala Azar Dermal Leishmaniasis
Intervention: Biological: LEISH-F2 + MPL-SE vaccine
17 Recruiting Micropulse Laser for Geographic Atrophy
Conditions: Geographic Atrophy;   Age-related Macular Degeneration
Intervention: Procedure: Micropulse
18 Withdrawn Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)
Condition: Type I Hypersensitivity
Intervention: Biological: RagweedMATAMPL
19 Completed Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine 208129;   Biological: Engerix™-B
20 Completed Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine;   Biological: Engerix™-B

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years